Written question asked by Lord Hunt of Kings Heath (Labour) on Tuesday, 29 October 2019, in the House of Lords. It was due for an answer on Tuesday, 12 November 2019. It was answered by Baroness Blackwood of North Oxford (Conservative) on Monday, 4 November 2019 on behalf of the Department of Health and Social Care.
Liothyronine
- Question
-
To ask Her Majesty's Government what price to the NHS liothyronine would need to fall below in order for the restriction on its prescription to be lifted.
- Answer
-
The Department would not intervene in determining what price to the National Health Service liothyronine would need to fall below in order for the restriction on its prescription to be lifted.
Liothyronine is only appropriate for a certain group of patients and the South Regional Medicines Optimisation Committee advice sought to provide further clinical guidance on this matter. Whilst NHS England and NHS Improvement will regularly review its guidance, at present, there are no plans to revisit the specific recommendations for liothyronine unless new clinical evidence comes to light.
Secondary information
- Type
- Written question
- Reference
- HL503
- Session
- 2019-19
- Subjects
- Prices Prescriptions Liothyronine
- Contains statistics
- Yes
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2019-12-11 16:32:51 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2019-19/HL503
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2019-19/HL503
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2019-19/HL503